CORCEPT THERAPEUTICS INC Cash and Cash Equivalents, Period Increase (Decrease)
CORCEPT THERAPEUTICS INC (CORT) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$10.36 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-24.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-02-24
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $2.06M.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $2.00K, a 99.95% decline year-over-year.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$2.56M, a 142.18% decline year-over-year.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$4.35M, a 516.56% decline year-over-year.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$10.36M, a 198.04% decline from fiscal 2018.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2018 was $10.56M.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$20.47M, a 284.43% decline from fiscal 2016.
- CORCEPT THERAPEUTICS INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was $11.10M, a 31.42% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 158 month | Cash and Cash Equivalents, Period Increase (Decrease) 161 month | Cash and Cash Equivalents, Period Increase (Decrease) 164 month | Cash and Cash Equivalents, Period Increase (Decrease) 167 month |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | -$10.36M 10-K · filed 2020-02-24 | |||||||
| 2018-12-31 | $10.56M 10-K · filed 2020-02-24 | |||||||
| 2018-03-31 | $2.06M 10-Q · filed 2018-05-09 | $2.06M derived: sum of 2 quarters · filed 2020-02-24 | -$502.00K derived: sum of 3 quarters · filed 2020-02-24 | -$4.86M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$2.56M derived: sum of 2 quarters · filed 2020-02-24 | -$6.91M derived: sum of 3 quarters · filed 2020-02-24 | -$20.47M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | -$2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$6.92M derived: sum of 2 quarters · filed 2017-11-03 | -$20.48M 10-Q · filed 2017-11-03 | -$16.80M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | -$4.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$17.91M 10-Q · filed 2017-08-02 | -$14.24M derived: sum of 3 quarters · filed 2019-02-26 | -$8.17M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | -$13.56M 10-Q · filed 2018-05-09 | -$9.89M derived: sum of 2 quarters · filed 2019-02-26 | -$3.81M derived: sum of 3 quarters · filed 2019-02-26 | -$2.77M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | $3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $9.75M derived: sum of 2 quarters · filed 2019-02-26 | $10.79M derived: sum of 3 quarters · filed 2019-02-26 | $11.10M 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $6.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $7.12M derived: sum of 2 quarters · filed 2017-11-03 | $7.43M 10-Q · filed 2017-11-03 | $11.41M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $1.35M 10-Q · filed 2017-08-02 | $5.34M derived: sum of 3 quarters · filed 2018-02-28 | $4.74M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2016-03-31 | $309.00K 10-Q · filed 2017-05-02 | $4.29M derived: sum of 2 quarters · filed 2018-02-28 | $3.70M derived: sum of 3 quarters · filed 2018-02-28 | $2.79M derived: sum of 4 quarters · filed 2018-02-28 | ||||
| 2015-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $3.39M derived: sum of 2 quarters · filed 2018-02-28 | $2.48M derived: sum of 3 quarters · filed 2018-02-28 | $16.19M 10-K · filed 2018-02-28 | ||||
| 2015-09-30 | -$598.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$1.50M derived: sum of 2 quarters · filed 2016-11-02 | $12.20M 10-Q · filed 2016-11-02 | $9.67M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-06-30 | -$905.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $12.80M 10-Q · filed 2016-08-03 | $10.27M derived: sum of 3 quarters · filed 2017-03-06 | $3.07M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-03-31 | $13.71M 10-Q · filed 2016-05-04 | $11.17M derived: sum of 2 quarters · filed 2017-03-06 | $3.98M derived: sum of 3 quarters · filed 2017-03-06 | -$5.67M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2014-12-31 | -$2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$9.73M derived: sum of 2 quarters · filed 2017-03-06 | -$19.37M derived: sum of 3 quarters · filed 2017-03-06 | -$30.63M 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | -$7.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$16.84M derived: sum of 2 quarters · filed 2015-11-06 | -$28.10M 10-Q · filed 2015-11-06 | -$36.40M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2014-06-30 | -$9.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$20.90M 10-Q · filed 2015-08-07 | -$29.20M derived: sum of 3 quarters · filed 2016-03-10 | -$38.25M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2014-03-31 | -$11.26M 10-Q · filed 2015-05-08 | -$19.56M derived: sum of 2 quarters · filed 2016-03-10 | -$28.60M derived: sum of 3 quarters · filed 2016-03-10 | -$37.84M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2013-12-31 | -$8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$17.34M derived: sum of 2 quarters · filed 2016-03-10 | -$26.58M derived: sum of 3 quarters · filed 2016-03-10 | -$38.16M 10-K · filed 2016-03-10 | ||||
| 2013-09-30 | -$9.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$18.29M derived: sum of 2 quarters · filed 2014-11-07 | -$29.86M 10-Q · filed 2014-11-07 | -$38.45M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2013-06-30 | -$9.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$20.81M 10-Q · filed 2014-08-08 | -$29.41M derived: sum of 3 quarters · filed 2015-03-13 | $37.32M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2013-03-31 | -$11.57M 10-Q · filed 2014-05-12 | -$20.17M derived: sum of 2 quarters · filed 2015-03-13 | $46.56M derived: sum of 3 quarters · filed 2015-03-13 | $38.83M derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2012-12-31 | -$8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $58.13M derived: sum of 2 quarters · filed 2015-03-13 | $50.41M derived: sum of 3 quarters · filed 2015-03-13 | $53.40M 10-K · filed 2015-03-13 | ||||
| 2012-09-30 | $66.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $59.00M derived: sum of 2 quarters · filed 2013-11-12 | $61.99M 10-Q · filed 2013-11-12 | $55.72M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-06-30 | -$7.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$4.74M 10-Q · filed 2013-08-09 | -$11.01M derived: sum of 3 quarters · filed 2014-03-14 | -$17.33M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-03-31 | $2.99M 10-Q · filed 2013-05-08 | -$3.28M derived: sum of 2 quarters · filed 2014-03-14 | -$9.60M derived: sum of 3 quarters · filed 2014-03-14 | -$16.57M derived: sum of 4 quarters · filed 2014-03-14 | $42.63M 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | -$6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | -$12.60M derived: sum of 2 quarters · filed 2014-03-14 | -$19.57M derived: sum of 3 quarters · filed 2014-03-14 | $15.06M 10-K · filed 2014-03-14 | $39.63M 10-K · filed 2012-03-13 | |||
| 2011-09-30 | -$6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$13.29M derived: sum of 2 quarters · filed 2012-11-08 | $21.33M 10-Q · filed 2012-11-08 | $16.93M derived: sum of 4 quarters · filed 2013-03-15 | $45.91M 10-Q · filed 2011-11-08 | |||
| 2011-06-30 | -$6.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $27.65M 10-Q · filed 2012-08-09 | $23.25M derived: sum of 3 quarters · filed 2013-03-15 | $16.84M derived: sum of 4 quarters · filed 2013-03-15 | $52.23M 10-Q · filed 2011-08-09 | |||
| 2011-03-31 | $34.62M 10-Q · filed 2012-05-10 | $30.23M derived: sum of 2 quarters · filed 2013-03-15 | $23.82M derived: sum of 3 quarters · filed 2013-03-15 | |||||
| 2010-12-31 | -$4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | -$10.81M derived: sum of 2 quarters · filed 2013-03-15 | $711.00K 10-K · filed 2013-03-15 | |||||
| 2010-09-30 | -$6.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $5.11M 10-Q · filed 2011-11-08 | ||||||
| 2010-06-30 | $11.52M 10-Q · filed 2011-08-09 | |||||||
| 2009-12-31 | $9.15M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |